viewCytoDyn Inc.

CytoDyn updates on Type A meeting with FDA, gets nod from UK proceed with Phase 3 coronavirus trial

CytoDyn Inc (OTCQB:CYDY) Nader Pourhassan tells Proactive it will submit questions regarding its Biologics License Application for leronlimab as an HIV therapy to the FDA in writing instead of holding a virtual Type A meeting, and the FDA has agreed to respond to said questions by September 4.

Pourhassan adds in the UK, the clinical trials unit of the country’s Medicines & Healthcare product Regulatory Agency authorized CytoDyn to enroll patients in its ongoing Phase 3 trial of leronlimab in severe-to-critical coronavirus patients.

Quick facts: CytoDyn Inc.

Price: 2.46 USD

Market: OTCQB
Market Cap: $1.4 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...


CytoDyn provide update on their path to approval for treatment of COVID-19

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to provide an update on how and when they expect to have approval for Leronlimab for Covid treatment.  Pourhassan also told Proactive about what the recent decision by the FDA to approve Remdesivir as a...

2 days, 7 hours ago

2 min read